Image by National Institutes of Allergy and Infectious Diseases
UC San Francisco scientists have discovered a new way to control the immune systemâs ânatural killerâ (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies to detect and destroy lurking tumors.Â
The study, published Jan. 8, 2021, in the
Journal of Experimental Medicine, addresses a major challenge for the field of regenerative medicine, said lead author Tobias Deuse, MD, the Julien I.E. Hoffman, MD, Endowed Chair in Cardiac Surgery in the UCSF Department of Surgery.Â
Sana Biotechnology Announces Appointments to its Board of Directors
Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors
News provided by
Share this article
Share this article
SEATTLE, Jan. 8, 2021 /PRNewswire/ Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, have been appointed to the Sana Board of Directors. Josh, Alise, and Michelle all share a passion and commitment to our long-term vision of engineering cells to make medicines that improve the lives of patients, said Sana President and CEO Steve Harr. The diversity of their experiences, backgrounds, and expertise will be critical to our strategy, decision-making, risk-management, and governance. I look forward to working with them to continue to build Sana.